Balancing Innovation and Affordability in China’s Healthcare System

Key Takeaways

• Central regulators are advancing market-driven pricing and diversified payment mechanisms for innovative drugs, aiming to improve healthcare fund allocation while incentivizing biotech innovation.
• A tiered diagnosis and treatment system to improve efficiency and clinical outcomes has become a core institutional priority.
• In recent meetings with USCBC, top Chinese healthcare regulators signaled openness to US companies’ participation in China’s healthcare and innovation ecosystem.